期刊文献+

直肠癌根治术加侧方淋巴结清扫术与单纯根治性手术比较的Meta分析 被引量:3

Lateral lymph node dissection with radical surgery versus single radical surgery for rectal cancer:a Meta analysis
原文传递
导出
摘要 目的:评价直肠癌侧方淋巴结清扫术(lateral lymph node dissection, LLND)在直肠癌根治术中的价值.方法:检索国内外公开发表的有关直肠癌LLND的中文和英文文献,最终符合入选标准的文献共15篇,包含4 858例患者,其中LLND组2 401例,NLLND组(非LLND)2 457例.评价指标包括5年生存率、复发率、围手术期情况以及术后泌尿系统功能和性功能情况等.结果: NLLND组的手术时间较LLND组明显缩短[加权均数差(weighted mean difference, WMD)为109 min,95% 可信区间(confidence interval,CI)为90~129,P<0.000 01];LLND组的术中失血量大于NLLND组,但差异无统计学意义(WMD为429 mL,95%CI为325~854,P=0.05);LLND组的围手术期并发症发生率明显高于NLLND组[比值比(odds ratio,OR)为1.57,95%CI为1.06~2.33,P=0.02].LLND组与NLLND组的手术后5年生存率差异无统计学意义(OR为0.94,95%CI为0.78~1.12,P=0.48);LLND组与NLLND组总的手术后复发率差异无统计学意义(OR为0.92,95%CI为0.70~1.22,P=0.57).此外,NLLND组发生泌尿系统功能障碍的可能性低于LLND组(OR为5.12,95%CI为2.15~12.19,P=0.000 2);个别研究报道NLLND组男性患者的性功能障碍发生率低于LLND组(P<0.05).结论:Meta分析结果显示,LLND组在降低术后复发率和延长生存期方面未显示出明显优势,但LLND组的围手术期并发症发生率有所增加、手术时间延长、手术出血量增加,术后性功能和泌尿系统功能障碍的发生率也均有所增加. Objective:To assess the value of lateral lymph node dissection (LLND) in the radical surgery of rectal cancer. Methods:The published Chinese and English literature about LLND was retrieved. Totally 15 literature fitted the selection criteria, which included 4 858 patients. Among them 2 401 patients were in LLND group and 2 457 patients in non-LLND (NLLND) group. The evaluation parameters included 5-year survival rate, recurrence rate, peri-operative outcomes, postoperative urinary and sexual fimctions. Results:The operating time was significantly shorter in the NLLND group than that in the LLND group [ weighted mean difference (WMD) = 109 min, 95% confidence interval(CI) : 90-129; P 〈0. 000 011- Intra-operative blood loss was greater in the LLND group than that in the NLLND group but the difference was not significant ( WMD = 429 mL, 95% CI: 325-854 ;P = 0.05 ). The frequency of peri-operative morbidity (OR: 1.57 95% CI: 1.06-2.33 ;P = 0.02) was significantly higher in the LLND groups compared with the NLLND group. There were no significant differences in 5-year survival rate ( OR: 0. 94, 95% CI: 0. 78-1. 12;P =0.48), and recurrence rate (OR: 0. 92, 95% CI: 0. 70-1.22;P = 0.57) between the two groups. Data from individual studies( three studies) showed that the frequency of male urinary dysfunction (OR: 5.12, 95 % CI: 2.15-12.19; P = 0. 000 2 ) and sexual dysfunction (P 〈 0.05 ) were greatly lower in the NLLND group than those in the LLND group, Conclusion:Meta analysis showed that LLND did not have specific advantage in decreasing postoperative recurrence and prolonging survival time, LLND was associated with prolonged operation time, in- creased blood loss, and elevated incidence of peri-operative complications and urinary, and sexual dysfunction.
出处 《肿瘤》 CAS CSCD 北大核心 2010年第8期676-681,共6页 Tumor
基金 江西省教育厅科学技术研究项目(编号:GJJ08120)
关键词 直肠肿瘤 结直肠外科手术 侧方淋巴结切除术 手术中并发症 手术后并发症 存活率分析 META分析 Rectal neoplasms Colorectal surgery Lateral lymph node excision Intraoperative complications Postoperative complications Survival analysis Meta-analysis
  • 相关文献

参考文献18

  • 1HIDA J,YASUTOMI M,FUJIMOTO K,et al.Does lateral lymph node dissection improve survival in rectal carcinoma? Examination of node metastases by the clearing method[J].J Am Coll Surg,1997,184(5):475-480.
  • 2SUGIHARA K,MORIYA Y,AKASU T,et al.Pelvic autonomic nerve preservation for patients with rectal carcinoma.Oncologic and functional outcome[J].Cancer,1996,78(9):1871-1880.
  • 3NAGAWA H,MUTO T,SUNOUCHI K,et al.Randomized,controlled trial of lateral node dissection vs nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy[J].Dis Colon Rectum,2001,44(9):1274-1280.
  • 4FUJITA S,YAMAMOTO S,AKASU T,et al.Lateral pelvic lymph node dissection for advanced lower rectal cancer[J].Br J Surg,2003,90(12):1580-1585.
  • 5HASDEMIR O,COL C,YALCIN E,et al.Local recurrence and survival rates after extended systematic lymph-node dissection for surgical treatment of rectal cancer[J].Hepatogastroenterology,2005,52(62):455-459.
  • 6刘宝善,燕锦,左明,刘超,徐琳.直肠癌侧方淋巴结清扫的效果分析[J].中华外科杂志,2004,42(15):908-910. 被引量:42
  • 7SUZUKI K,MUTO T,SAWADA T.Prevention of local recurrence by extended lymphadenectomy for rectal cancer[J].Surg Today,1995,25(9):795-801.
  • 8MATSUOKA H,MASAKI T,SUGIYAMA M,et al.Impact of lateral pelvic lymph node dissection on evacuatory and urinary functions following low anterior resection for advanced rectal carcinoma[J].Langenbecks Arch Surg,2005,390(6):517-522.
  • 9MOREIRA L F,HIZUTA A,IWAGAKI H,et al.Lateral lymph node dissection for rectal carcinoma below the peritoneal reflection[J].Br J Surg,1994,81(2):293-296.
  • 10SHIOZAWA M,AKAIKE M,YAMADA R,et al.Lateral lymph node dissection for lower rectal cancer[J].Hepatogastroenterology,2007,54(76):1066-1070.

二级参考文献29

  • 1RIVERA F, VEGA-VILLEGAS M E, LOPEZ-BREA M F, et al. Cetuximab, its clinical use and future perspectives [ J ]. Anticancer Drugs, 2008,19 (2) :99-113.
  • 2CUNNINGHAM D, HUMBLET Y, SIENA S,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer[ J]. N Engl J Med, 2004, 351 (4) :337- 345.
  • 3JADAD A R, MOORE R A, CARROLL D, et al. Assessing the quality of reports of randomized clinical trials : is blinding necessary [ J ]. Control Clin Trials, 1996,17 ( 1 ) : 1-12.
  • 4CIULEANU T E, KURTEVA G, OCVIRK J, et al. A randomized, open-label CECOG phase Ⅱ study evaluating the efficacy and safety of FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) [ J ]. J Clin Oncol, 2008, 26 (Suppl) : abstr 4032.
  • 5ALDERSON P, GREEN S, HIGGINS J P T, et al. Cochrane reviewers' handbook 4.2.3 [ R ]. In : The Cochrane Library [ DB ]. UK: John Wiley & Sons, Ltd. , 2004:68-139.
  • 6TEJPAR S, PEETERS M, HUMBLET Y, et al. Phase Ⅰ/Ⅱ study of cetuximab dose-escalation in patients with metastatic colorectal cancer ( mCRC ) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK) , pharmacodynamic (PD) and efficacy data[ J]. J Clin Oncol, 2007, 25 ( 18 S) : abstr 4037.
  • 7HEINEMANN V, FISCHER VON WEIKERSTHAL L, VEHLING- KAISER U, et al. Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC) : A study of the German AIO CRC study group[ J]. J Clin Oncol, 2008, 26( Sup- pl) :abstr 4033.
  • 8SALTZ LB, LENZ H J, KINDLER HL, et al. Randomized phase Ⅱ trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study [ J ]. J Clin Oncol, 2007, 25 (29) : 4557-4561.
  • 9SOBRERO AF, MAUREL J, FEHRENBACHER L, et al. EPIC: Phase Ⅲ trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2008, 26(14) :2311-2319.
  • 10VAN CUTSEM E, NOWACKI M, LANG I, et al. Randomized phase Ⅲ study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial [ J ]. J Clin Oncol, 2007, 25 (16s) :4000.

共引文献47

同被引文献34

  • 1王伟建,马天星,于秀芝.双吻合器保肛术治疗低位直肠癌效果观察[J].河南外科学杂志,2009,15(1):50-51. 被引量:1
  • 2董新舒,徐海涛.提高结直肠癌综合治疗的水平[J].结直肠肛门外科,2006,12(1):18-22. 被引量:10
  • 3刘超,刘宝善,燕锦,徐琳,左明,郑阳春.低位直肠癌不同切除范围的疗效分析[J].四川肿瘤防治,2007,20(2):103-105. 被引量:4
  • 4上海市肿瘤研究所流行病研究室.1999年上海市区恶性肿瘤发病率报告.肿瘤,2003,.
  • 5Japanese Society for Cancer of the Colon and Rectum.Guidelines for Colon and Rectal Cancer 2005[M].Kanehara:Tokyo,2005.
  • 6Ueno H,Yamauchi C,Hase K,et al.Clinicopathological study of intrapelvic cancer spread to the iliac area in lower rectal adenocarcinoma by serial sectioning[J].Br J Surg,1999,86 (12):1532.
  • 7Morita T,Murata A,Koyama M,et al.Current status of autonomic nerve-preserving surgery for mid and lower rectal cancers:Japanese experience with lateral node dissection[J].Dis Colon Rectum,2003,46 (10 Suppl):S78.
  • 8Yamaguchi T,Mori T,Takahashi K,et al.Controversy about treatment of colorectal cancer in view of surgeon--lymph node dissection for colorectal surgery (lateral lymph node dissection and TME)[J].Gan To Kagaku Ryoho,2003,30(9):1256.
  • 9Koda K,Saito N,Oda K,et al.Evaluation of lateral lymph node dissection with preoperative chemo-radiotherapy for the treatment of advanced middle to lower rectal cancers[J].Int J Colorectal Dis,2004,19(3):188.
  • 10Sugihara K,Kobayashi H,Kato T,et al.Indication and benefit of pelvic sidewall dissection for rectal cancer[J].Dis Colon Rectum,2006,49(11):1663.

引证文献3

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部